A Silent Saboteur of Immunotherapy: Antibiotic Use and Its Impact on Immune Checkpoint Inhibitors Efficacy, a Systematic Review and Meta-Analysis of Recent Studies
Giuliana Ciappina(University of Ferrara), Massimiliano Berretta(University of Messina), Oreste Claudio Buonomo(University of Basilicata), Antonio Bottari(University of Messina), Gaetano Facchini(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), Alessandro Ottaiano(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Guglielmo Nasti, Nicola Maurea(Cancer Institute (WIA)), Tindara Franchina(University of Messina), Enrica Toscano(University of Messina), Mariapia Marafioti(University of Messina), Vincenzo Quagliariello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesca Wanda Basile(University of Messina), Giordana Di Mauro(University of Messina), Gianluca Vanni(Policlinico Tor Vergata)
Cited by 1
Related Papers
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
FGFR a promising druggable target in cancer: Molecular biology and new drugs
|Critical Reviews in Oncology/Hematology|2017|203
Epithelial-mesenchymal transition in prostate cancer: an overview
|Oncotarget|2017|177
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108